RMTI logo

Rockwell Medical, Inc. Stock Price

NasdaqCM:RMTI Community·US$31.5m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 15 Fair Values set on narratives written by author

RMTI Share Price Performance

US$0.82
-0.18 (-17.65%)
US$4.00
Fair Value
US$0.82
-0.18 (-17.65%)
79.5% undervalued intrinsic discount
US$4.00
Fair Value
Price US$0.82
AnalystHighTarget US$4.00
AnalystConsensusTarget US$3.00
AnalystLowTarget US$2.00

RMTI Community Narratives

·
Fair Value US$4 79.5% undervalued intrinsic discount

Aging And Home Care Trends Will Raise Demand Amid Risks

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
·
Fair Value US$3 72.7% undervalued intrinsic discount

Dialysis Demand Will Grow Despite Margin And Market Challenges

0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
·
Fair Value US$2 59.0% undervalued intrinsic discount

Dialysis Loss Will Squeeze Margins Yet Yield Cautious Relief

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US$2
59.0% undervalued intrinsic discount
Profit Margin
5.91%
Future PE
24.34x
Price in 2029
US$2.53

Trending Discussion

Updated Narratives

RMTI logo

RMTI: Dialysis Contract Wins Will Drive Future Repricing Potential

Fair Value: US$2 59.0% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
RMTI logo

RMTI: Reset Price Views Will Highlight Rebound In Growth Expectations

Fair Value: US$3 72.7% undervalued intrinsic discount
7 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
RMTI logo

RMTI: Future Earnings Framework Will Center On Execution And Margin Discipline

Fair Value: US$4 79.5% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with low risk.

3 Risks
0 Rewards

Rockwell Medical, Inc. Key Details

US$67.7m

Revenue

US$56.1m

Cost of Revenue

US$11.6m

Gross Profit

US$17.1m

Other Expenses

-US$5.6m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-0.14
17.07%
-8.21%
24.6%
View Full Analysis

About RMTI

Founded
1996
Employees
157
CEO
Mark Strobeck
WebsiteView website
www.rockwellmed.com

Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers. The company’s hemodialysis concentrate products are used to sustain patient’s life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. In addition, it offers dialysis concentrates, dialysis kits, and other ancillary products used in the dialysis process. The company was formerly known as Rockwell Medical Technologies, Inc. and changed its name to Rockwell Medical, Inc. in June 2012. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

Recent RMTI News & Updates

Narrative Update May 17

RMTI: Dialysis Contract Wins Will Drive Future Repricing Potential

Rockwell Medical's analyst price target has shifted lower from $2.50 to $2.00, as analysts factor in updated assumptions around fair value, profitability, and a higher expected future P/E multiple, as reflected in recent research updates. Analyst Commentary Recent research updates on Rockwell Medical reflect a more cautious tone, with bearish analysts trimming price targets and reassessing the risk and reward tradeoff.

Recent updates

No updates